- Distribution agreement effective May 1st 2023
- New agreement applies to the polymers of the Medical Care series portfolio consisting of VESTAMID® Care ML, VESTAMID® Care ME, TROGAMID® Care MX, VESTAKEEP® Care, VESTODUR®
- Complementary Evonik and IMCD portfolios enable further synergies within the Medical and Healthcare markets
According to the company’s website press release on May 2, 2023, IMCD, a global leader in the distribution of specialty chemicals and ingredients has entered into a strategic distribution agreement with Evonik, a specialty chemicals company. Under this agreement, IMCD will serve as Evonik’s European distributor for its Medical Care series, covering EEA countries including the United Kingdom and Switzerland. This partnership represents a step forward for IMCD in expanding its presence in the market segment of medical devices. Set to take effect on 1 May 2023, this agreement will enable Evonik to expand its reach and to better serve its customers.
As a distributor with a strong presence in medical and healthcare applications, IMCD offers a dedicated medical application team, which makes the company an ideal partner for Evonik's European customers. Expanding the IMCD medical polymer portfolio with Evonik’s Medical Care Series will create synergies that offer new opportunities for medical industry customers in various applications like medical tubing, dialyzer parts, surgical instruments, and inhalers.
“We are confident that this partnership with IMCD will enable us to address the evolving requirements in the medical sector,” said Dr. Philip Engel, Head of Medical Systems Europe at of Evonik, “IMCD brings extensive market knowledge and technical expertise that we can rely on to meet the needs of our customers in order to accelerate further business growth.”
Jana Zietzling, Head of Product Management Medical at IMCD Business Group Advanced Materials, “We are excited to partner with Evonik and add their high-performance polymers to our portfolio. By leveraging our shared commitment to innovation and our in-depth knowledge in medical polymers and applications, we are able to support customers even better in their product development of medical devices.”
ABOUT EVONIK
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €18.5 billion and an operating profit (adjusted EBITDA) of €2.49 billion in 2022. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. About 34,000 employees work together for a common purpose: We want to improve life today and tomorrow.
ABOUT IMCD GROUP
The IMCD Group, based in Rotterdam, the Netherlands, is a global market leader in the marketing, sales, and distribution of speciality chemicals and ingredients. Its result-driven professionals provide market-focused solutions to suppliers and customers across EMEA, Americas and Asia-Pacific, offering comprehensive product portfolios ranging from home, industrial and institutional care, beauty and personal care, food and nutrition and pharmaceuticals to lubricants and energy, coatings and construction, advanced materials, and industrial solutions.
The IMCD Group realised revenues of EUR 4,601 million in 2022 with more than 4,300 employees in over 50 countries. IMCD's dedicated team of technical and commercial experts work in close partnership to tailor best-in-class solutions and provide value through expertise for around 50,000 customers and a diverse range of world-class suppliers. IMCD shares are traded at Euronext, Amsterdam (IMCD).
For further information, please visit www.imcdgroup.com.
DISCLAIMER
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.
